I bet GSK buys shire. Vyvanse has other indications pending and it won't go generic any time soon. With lamictal generic they have an entire neuro division with nothing to sell. They need vyvanse to have a reason to stay in these offices. The co-promote won't last long... When the co-promote is a success GSK will buy shire if another big pharma doesn't buy them first.